A Maltose-Binding Protein Fusion Construct Yields a Robust Crystallography Platform for MCL1Matthew C. Clifton, Michael H. Serrano‐Wu, Dazhong Fan et al.|PLoS ONE|2015Cited by 34
BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Michael H. Serrano‐Wu et al.|Nature Cancer|2024Cited by 28
Abstract LB_A01: Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivoUlrike Rauh, Todd R. Golub, Virendar K. Kaushik et al.|Molecular Cancer Therapeutics|2023Cited by 1
Binding affinity (K<sub>D</sub>) of ligands to MCL1 and MBP-MCL1.Matthew C. Clifton, Michael H. Serrano‐Wu, David M. Dranow et al.|Figshare|2015Cited by 0